Clearview Cancer Institute-Decatur — Decatur, Alabama

Clearview Cancer Institute-Decatur is a clinical research site located in Decatur, Alabama, United States 35601.

Crixeo Clinical Trials Trust Score: 4/100 (FAILING). This profile has not yet been claimed by the site owner.

Clearview Cancer Institute-Decatur has participated in 1 clinical trials.

Therapeutic areas: Breast Cancer.

Sponsors: NSABP Foundation Inc.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Decatur

Browse all research sites in Alabama · View every site in Decatur

• Decatur General Hospital
• Research Site
• Furiex Research Site
• Decatur Ambulatory Surgery Center
• Nephrology of North Alabama
• GSK Investigational Site
• ImClone Investigational Site
• Atlanta VAHCS /ID# 170318
• Parents and Children Together
• Decatur Orthopaedic Clinic
• Local Institution
• Atlanta VAMC /ID# 215763

Sponsor Feasibility Report

Trust Score: 4/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Clearview Cancer Institute-Decatur?

Clearview Cancer Institute-Decatur has a Crixeo Trust Score of 4/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Clearview Cancer Institute-Decatur conducted?

Clearview Cancer Institute-Decatur has 1 clinical trials on record. Their work covers Breast Cancer.

Is Clearview Cancer Institute-Decatur accredited by Crixeo Clinical Trials?

Clearview Cancer Institute-Decatur has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Clearview Cancer Institute-Decatur?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.